百济神州 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BEONE MEDICINES LTD. Securities registered pursuant to Section 12(b) of the Act: *Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary sharesare not listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.As of April30, 2026, 1,445,262,342 ordinary shares, par value $0.0001 per share, were outstanding, of which 713,513,697 ordinary shares were held in the form of 54,885,669 American Depositary Shares, each representing 13 ordinary shares, and 115,055,260 were RMB shares which are ordinaryshares issued to permitted investors in China and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange inRenminbi. Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to suchfiling requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Non-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ BeOne Medicines Ltd.Quarterly Report on Form 10-QTABLE OF CONTENTS PARTI.FINANCIAL INFORMATION3Item 1.Financial Statements3Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations26Item 3.Quantitative and Qualitative Disclosures about Market Risk39Item 4.Controls and Procedures40PARTII.OTHER INFORMATION41Item 1.Legal Proceedings41Item 1A.Risk Factors41Item 2.Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities100Item 3.Defaults Upon Senior Securities100Item 4.Mine Safety Disclosures100Item 5.Other Information100Item 6.Exhibits101SIGNATURES103 From time to time, we may use our website, our X account at x.com/BeOneMedicines, our LinkedIn account atlinkedin.com/company/BeOneMedicines, our Facebook account at facebook.com/BeOneMedicines, and our Instagram account atinstagram.com/BeOneMedicines to disclose material information and to comply with our disclosure obligations under Regulation FD.Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available atwww.beonemedicines.com. Investors are encouraged to review the Investors section of our website because we may post materialinformation on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through ourwebsite, our X posts, our LinkedIn posts and our Instagram posts are not incorporated into, and does not form a part of, this QuarterlyReport. PART I.FINANCIAL INFORMATION BEONE MEDICINESLTD.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)(Unaudited) (Unaudited) BEONE MEDICINESLTD.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Amounts in thousands of U.S. Dollars (“$”))(Unaudited) 1.Upon effectiveness of the Continuation, ordinary shares (including in the form of ADS) held by the Company or one of its controlled subsidiaries immediatelyprior to the effective date of the Continuation became part of the Company’s issued but not outstanding share capital and are considered ordinary shares of theCompany, or “treasury shares” under Swiss law. The Company expects to use these treasury shares in the future to satisfy obligations to deliver shares inconnection with awards granted under the Company’s equity incentive plans and agreements. The accompanying notes are an integral part of these condensed consolidated financial statements. BEONE MEDICINESLTD. NOTES TO THE CONDENSED CONSOLI